Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer
Pembrolizumab alone and in combination with acalabrutinib in subjects with advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
DRUG: Pembrolizumab|DRUG: Acalabrutinib
Number of Participants With Overall Response, Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR, Every 12 weeks for up to 2 years
Pembrolizumab alone and in combination with acalabrutinib in subjects with advanced non-small cell lung cancer.